AtriCure (ATRC) vs Embecta (EMBC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed Embecta (EMBC) over the past year, gaining 56.2% versus a loss of 57.1%. AtriCure is the larger company by market cap ($2.71 billion vs $334.9 million), about 8.1 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 122.8x for AtriCure).
Embecta pays a dividend yielding 7.78%, while AtriCure does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | EMBC |
|---|---|---|
| Share price | $53.31 | $5.91 |
| Market cap | $2.71B | $334.86M |
| 1-day change | -0.69% | -0.67% |
| YTD return | +34.76% | -50.25% |
| 1-year return | +56.24% | -57.11% |
| 5-year return | -25.30% | — |
| P/E ratio (TTM) | 253.86 | 4.02 |
| Forward P/E | 122.84 | 3.35 |
| EPS (TTM) | $0.21 | $1.47 |
| Dividend yield | 0.00% | 7.78% |
| Annual dividend | $0.00 | $0.46 |
| Revenue (latest FY) | $534.53M | — |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | — |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | — |
| Net margin | -2.14% | — |
| 52-week high | $61.70 | $14.91 |
| 52-week low | $25.36 | $2.77 |
| Distance from 52-week high | -13.60% | -60.36% |
| Analyst consensus | buy | none |
| Avg. price target upside | +2.96% | -32.32% |
| Average volume | 1.10M | 1.38M |
| Shares outstanding | 50.87M | 56.66M |
| Employees | 1,350 | 1,850 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure is about 8.1 times larger than Embecta by market value ($2.71B vs $334.86M).
- ATRC has outperformed EMBC by 113.4 percentage points over the past year.
- AtriCure trades at a higher earnings multiple (253.9x vs 4.0x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (7.78% vs 0.00%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
ATRC vs EMBC FAQ
Which is bigger, AtriCure or Embecta?
AtriCure (ATRC) is larger, with a market capitalization of $2.71B compared with $334.86M for Embecta (EMBC).
Which stock has performed better over the past year, ATRC or EMBC?
ATRC returned +56.24% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or EMBC?
EMBC has the lower trailing P/E at 4.0, versus 253.9 for ATRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AtriCure or Embecta?
Embecta pays a dividend yielding 7.78%, while AtriCure does not currently pay a regular dividend.
Are AtriCure and Embecta in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.